Publisher
Springer Science and Business Media LLC
Reference40 articles.
1. Peri- and Postmenopause—Diagnosis and Interventions. Guideline of the DGGG, SGGG and OEGGG (S3 Level, AWMF Registry No. 015-062, January 2020). http://www.awmf.org/leitlinien/detail/ll/015-062.html (letzter Zugriff: 23. Jan. 2024).
2. Collaborative Group on Hormonal Factors in Breast Cancer. Type and timing of menopausal hormone therapy and breast cancer risk: individual participant meta-analysis of the worldwide epidemiological evidence. Lancet. 2019 Sep 28;394(10204):1159–1168. https://doi.org/10.1016/S0140-6736(19)31709-X. Epub 2019 Aug 29. PMID: 31474332; PMCID: PMC6891893.
3. Abenhaim HA, Suissa S, Azoulay L, Spence AR, Czuzoj-Shulman N, Tulandi T (2022) Menopausal Hormone Therapy Formulation and Breast Cancer Risk. Obstet Gynecol 1;139(6):1103–1110 (Jun)
4. Chlebowski RT, Anderson GL, Aragaki AK, Manson JE, Stefanick ML, Pan K, Barrington W, Kuller LH, Simon MS, Lane D, Johnson KC, Rohan TE, Gass MLS, Cauley JA, Paskett ED, Sattari M, Prentice RL (2020) Association of menopausal hormone therapy with breast cancer incidence and mortality during long-term follow-up of the women’s health initiative randomized clinical trials. JAMA 324(4):369–380
5. Prentice RL, Aragaki AK, Chlebowski RT, Rossouw JE, Anderson GL, Stefanick ML, Wactawski-Wende J, Kuller LH, Wallace R, Johnson KC, Shadyab AH, Gass M, Manson JE (2021) Randomized Trial Evaluation of the Benefits and Risks of Menopausal Hormone Therapy Among Women 50–59 Years of Age. Am J Epidemiol 1;190(3):365–375 (Feb)